Low concentrations of phospholipids and plasma HDL cholesterol subclasses in asymptomatic subjects with high coronary calcium scores

Atherosclerosis

Volumn 238, Issue 2, 2015, Pages 250-255

  García Sánchez, Cynthia ^a   Posadas Romero, Carlos ^a   Posadas Sánchez, Rosalinda ^a   Carreón Torres, Elizabeth ^a   Rodríguez Pérez, José Manuel ^a   Juárez Rojas, Juan Gabriel ^a   Martínez Sánchez, Carlos ^a   Fragoso, José Manuel ^a   González Pacheco, Héctor ^a   Vargas Alarcón, Gilberto ^a   Pérez Méndez, Óscar ^a  

^a INSTITUTO NACIONAL DE CARDIOLOGÍA IGNACIO CHÁVEZ   (Mexico)

Author keywords

Agatston score; Coronary artery disease; Dyslipidemia; High density lipoprotein subclasses; Risk factors; Subclinical atherosclerosis

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PHOSPHOLIPID DERIVATIVE; TRIACYLGLYCEROL; BIOLOGICAL MARKER; PHOSPHOLIPID;

ADULT; ARTICLE; ASYMPTOMATIC DISEASE; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CORONARY ARTERY CALCIUM SCORE; ELECTROPHORESIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; TRIACYLGLYCEROL BLOOD LEVEL; ULTRACENTRIFUGATION; AGE; ANGIOCARDIOGRAPHY; BLOOD; CORONARY ARTERY DISEASE; MEXICO; MULTIDETECTOR COMPUTED TOMOGRAPHY; PARTICLE SIZE; PROCEDURES; PROGNOSIS; RISK FACTOR; SEX DIFFERENCE; VASCULAR CALCIFICATION;

AGE FACTORS; ASYMPTOMATIC DISEASES; BIOLOGICAL MARKERS; CHOLESTEROL, HDL; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; FEMALE; HUMANS; MALE; MEXICO; MULTIDETECTOR COMPUTED TOMOGRAPHY; PARTICLE SIZE; PHOSPHOLIPIDS; PROGNOSIS; RISK FACTORS; SEX FACTORS; VASCULAR CALCIFICATION;

EID: 84919808107     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2014.12.004     Document Type: Article

References (46)

1. Assmann G., Schulte H., von Eckardstein A., Huang Y. High-density lipoprotein cholesterol as a predictor of coronary heart disease risk: the PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis 1996, 124:S11-S20.
2. Navab M., Reddy S.T., Van Lenten B.J., Fogelman A.M. HDL and cardiovascular disease: atherogenic and atheroprotective mechanisms. Nat. Rev. Cardiol. 2011, 8:222-232.
3. Rye K.A., Bursill C.A., Lambert G., Tabet F., Barter P.J. The metabolism and anti-atherogenic properties of HDL. J.Lipid Res. 2009, 50:S195-S200.
4. Pérez-Méndez O., Pacheco H.G., Martínez-Sánchez C., Franco M. HDL-cholesterol in coronary artery disease risk: function or structure?. Clin. Chim. Acta 2014, 429:111-122.
5. Williams P.T., Krauss R.M., Nichols A.V., Vranizan K.M., Wood P.D. Identifying the predominant peak diameter of high-density and low-density lipoproteins by electrophoresis. J.Lipid Res. 1990, 31:1131-1139.
6. Florentin M., Liberopoulos E.N., Wierzbicki A.S., Mikhailidis D.P. Multiple actions of high-density lipoprotein. Curr. Opin. Cardiol. 2008, 23:370-378.
7. Kimura T., Tomura H., Sato K., Ito M., Matsuoka I., Im D.S., et al. Mechanism and role of high density lipoprotein-induced activation of AMP-activated protein kinase in endothelial cells. J.Biol. Chem. 2010, 285:4387-4397.
8. Escolà-Gil J.C., Rotllan N., Julve J., Blanco-Vaca F. Invivo macrophage-specific RCT and antioxidant and antiinflammatory HDL activity measurements: new tools for predicting HDL atheroprotection. Atherosclerosis 2009, 206:321-327.
9. Pérez-Méndez O., Torres-Tamayo M., Posadas-Romero C., Vidaure Garcés V., Carreón-Torres E., Mendoza-Pérez E., et al. Abnormal HDL subclasses distribution in overweight children with insulin resistance or type 2 diabetes mellitus. Clin. Chim. Acta 2007, 376:17-22.
10. Magkos F., Mohammed B.S., Mittendorfer B. Effect of obesity on the plasma lipoprotein subclass profile in normoglycemic and normolipidemic men and women. Int. J. Obes. 2008, 32:1655-1664.
11. Morgan J., Carey C., Lincoff A., Capuzzi D. High-density lipoprotein subfractions and risk of coronary artery disease. Curr. Atheroscler. Rep. 2004, 6:359-365.
12. Juárez-Meavepeña M., Carreón-Torres E., López-Osorio C., García-Sánchez C., Gamboa R., Torres-Tamayo M., et al. The Srb1+1050T allele is associated with metabolic syndrome in children but not with cholesteryl ester plasma concentrations of high-density lipoprotein subclasses. Metab. Syndr. Relat. Disord. 2012, 10:110-116.
13. García-Sánchez C., Torres-Tamayo M., Juárez-Meavepeña M., López-Osorio C., Toledo-Ibelles P., Monter-Garrido M., et al. Lipid plasma concentrations of HDL subclasses determined by enzymatic staining on polyacrylamide electrophoresis gels in children with metabolic syndrome. Clin. Chim. Acta 2011, 412:292-298.
14. Festa A., Williams K., Hanley A.J., Otvos J.D., Goff D.C., Wagenknecht L.E., et al. Nuclear magnetic resonance lipoprotein abnormalities in prediabetic subjects in the insulin resistance atherosclerosis study. Circulation 2005, 111:3465-3472.
15. Detrano R., Guerci A.D., Carr J.J., Bild D.E., Burke G., Folsom A.R., et al. Coronary calcium as a predictor of coronary events in four racial or ethnic groups. N.Engl. J. Med. 2008, 358:1336-1345.
16. Vliegenthart R., Oudkerk M., Hofman A., Oei H.H., van Dijck W., van Rooij F.J., et al. Coronary calcification improves cardiovascular risk prediction in the elderly. Circulation 2005, 112:572-577.
17. Erbel R., Möhlenkamp S., Moebus S., Schmermund A., Lehmann N., Stang A., et al. Heinz nixdorf recall study investigative group. Coronary risk stratification, discrimination, and reclassification improvement based on quantification of subclinical coronary atherosclerosis: the heinz nixdorf recall study. J.Am. Coll. Cardiol. 2010, 56:1397-1406.
18. Agatston A.S., Janowitz W.R., Hildner F.J., Zusmer N.R., Viamonte M., Detrano R. Quantification of coronary artery calcium using ultrafast computed tomography. J.Am. Coll. Cardiol. 1990, 15:827-832.
19. Erbel R., Lehmann N., Churzidse S., Möhlenkamp S., Moebus S., Mahabadi A.A., et al. Heinz nixdorf recall study investigators. Gender-specific association of coronary artery calcium and lipoprotein parameters: the heinz nixdorf recall study. Atherosclerosis 2013, 229:531-540.
20. Martin S.S., Qasim A.N., Wolfe M., St Clair C., Schwartz S., Iqbal N., et al. Comparison of high-density lipoprotein cholesterol to apolipoprotein A-I and A-II to predict coronary calcium and the effect of insulin resistance. Am. J. Cardiol. 2011, 107:393-398.
21. Orakzai S.H., Nasir K., Blaha M., Blumenthal R.S., Raggi P. Non-HDL cholesterol is strongly associated with coronary artery calcification in asymptomatic individuals. Atherosclerosis 2009, 202:289-295.
22. Simprini L.A., Villines T.C., Rich M., Taylor A.J. The relationship between sub-clinical atherosclerosis, non-high-density lipoprotein cholesterol, exercise, and diet among male participants of the PACC project. J.Clin. Lipidol. 2012, 6:174-179.
23. Prado K.B., Shugg S., Backstrand J.R. Low-density lipoprotein particle number predicts coronary artery calcification in asymptomatic adults at intermediate risk of cardiovascular disease. J.Clin. Lipidol. 2011, 5:408-413.
24. Lommi J.I., Kovanen P.T., Jauhiainen M., Lee-Rueckert M., Kupari M., Helske S. High-density lipoproteins (HDL) are present in stenotic aortic valves and may interfere with the mechanisms of valvular calcification. Atherosclerosis 2011, 219:538-544.
25. Voros S., Joshi P., Qian Z., Rinehart S., Vazquez-Figueroa J.G., Anderson H., et al. Apoprotein B, small-dense LDL and impaired HDL remodeling is associated with larger plaque burden and more noncalcified plaque as assessed by coronary CT angiography and intravascular ultrasound with radiofrequency backscatter: results from the ATLANTA I study. J.Am. Heart Assoc. 2013, 2. e000344.
26. Villarreal-Molina T., Posadas-Romero C., Romero-Hidalgo S., Antúnez-Argurelles E., Bautista-Grande A., Vargas-Alarcón G., et al. The ABCA1 gene R230C variant is associated with decreased risk of premature coronary artery disease: the genetics of atherosclerotic disease (GEA) study. PLoS One 2012, 7. e49285.
27. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 2003, 26(Suppl.1):S5-S20.
28. Hoff J.A., Chomka E.V., Krainik A.J., Daviglus M., Rich S., Kondos G.T. Age and gender distributions of coronary artery calcium detected by electron beam tomography in 35,246 adults. Am. J. Cardiol. 2001, 87:1335-1339.
29. DeLong D.M., DeLong E.R., Wood P.D., Lippel K., Rifkind B.M. Acomparison of methods for the estimation of plasma low- and very low-density lipoprotein cholesterol. The lipid research clinics prevalence study. JAMA 1986, 256:2372-2377.
30. Carreón-Torres E., Juárez-Meavepeña M., Cardoso-Saldaña G., Gómez C.H., Franco M., Fievet C., et al. Pioglitazone increases the fractional catabolic and production rates of high-density lipoproteins apo AI in the New Zealand White Rabbit. Atherosclerosis 2005, 181:233-240.
31. Warnick G.R., McNamara J.R., Boggess C., Clendenen F., Williams P.T., Landolt C.C. Polyacrylamide gradient gel electrophoresis of lipoprotein subclasses. Clin. Lab. Med. 2006, 26:803-846.
32. Huesca-Gómez C., Carreón-Torres E., Nepomuceno-Mejía T., Sánchez-Solorio M., Galicia-Hidalgo M., Mejía A.M., et al. Contribution of cholesteryl ester transfer protein and lecithin: cholesterol acyltranferase to HDL size distribution. Endocr. Res. 2004, 30:403-415.
33. Toledo-Ibelles P., García-Sánchez C., Avila-Vazzini N., Carreón-Torres E., Posadas-Romero C., Vargas-Alarcón G., et al. Enzymatic assessment of cholesterol on electrophoresis gels for estimating HDL size distribution and plasma concentrations of HDL subclases. J.Lipid Res. 2010, 51:1610-1617.
34. Kaden J.J., Bickelhaupt S., Grobholz R., Haase K.K., Sarikoç A., Kiliç R., et al. Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulate aortic valve calcification. J.Mol. Cell. Cardiol. 2004, 36:57-66.
35. Min H., Morony S., Sarosi I., Dunstan C.R., Capparelli C., Scully S., et al. Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis. J.Exp. Med. 2000, 192:463-474.
36. Bucay N., Sarosi I., Dunstan C.R., Morony S., Tarpley J., Capparelli C., et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Gene Dev. 1998, 12:1260-1268.
37. Olsson M., Thyberg J., Nilsson J. Presence of oxidized low density lipoprotein in nonrheumatic stenotic aortic valves. Arterioscler. Thromb. Vasc. Biol. 1999, 19:1218-1222.
38. Rajamannan N.M., Subramaniam M., Stock S.R., Stone N.J., Springett M., Ignatiev K.I., et al. Atorvastatin inhibits calcification and enhances nitric oxide synthase production in the hypercholesterolaemic aortic valve. Heart 2005, 91:806-810.
39. Medina-Bravo P., Medina-Urrutia A., Juárez-Rojas J.G., Cardoso-Saldaña G., Jorge-Galarza E., Posadas-Sánchez R., et al. Glycemic control and high-density lipoprotein characteristics in adolescents with type 1 diabetes. Pediatr. Diabetes 2013, 14:399-406.
40. Yetukuri L., Söderlund S., Koivuniemi A., Seppänen-Laakso T., Niemelä P.S., Hyvönen M., et al. Composition and lipid spatial distribution of HDL particles in subjects with low and high HDL-cholesterol. J.Lipid Res. 2010, 51:2341-2351.
41. Choi J.M., Kim T.E., Cho J.Y., Lee H.J., Jung B.H. Development of lipidomic platform and phosphatidylcholine retention time index for lipid profiling of rosuvastatin treated human plasma. J.Chromatogr. B Anal. Technol. Biomed. Life Sci. 2014, 944:157-165.
42. Camont L., Lhomme M., Rached F., Le Goff W., Nègre-Salvayre A., Salvayre R., et al. Small, dense high-density lipoprotein-3 particles are enriched in negatively charged phospholipids: relevance to celular cholesterol efflux, antioxidative, antithrombotic, anti-inflammatory, and antiapoptotic functionalities. Arterioscler. Thromb. Vasc. Biol. 2013, 33:2715-2723.
43. Kontush A., Lhomme M., Chapman M.J. Unraveling the complexities of the HDL lipidome. J.Lipid Res. 2013, 54:2950-2963.
44. Otvos J.D., Collins D., Freedman D.S., Shalaurova I., Schaefer E.J., McNamara J.R., et al. LDL and HDL particle subclasses predict coronary events and are changed favorably by gemfibrozil therapy in the veterans affairs HDL intervention trial (VA-HIT). Circulation 2006, 113:1556-1563.
45. Budoff M.J., Achenbach S., Blumenthal R.S., Carr J.J., Goldin J.G., Greenland P., et al. Assessment of coronary artery disease by cardiac computed tomography: a scientific statement from the american heart association committee on cardiovascular imaging and intervention, council on cardiovascular radiology and intervention, and committee on cardiac imaging, council on clinical cardiology. Circulation 2006, 114:1761-1791.
46. Otocka-Kmiecik A., Mikhailidis D.P., Nicholls S.J., Davidson M., Rysz J., Banach M. Dysfunctional HDL: a novel important diagnostic and therapeutic target in cardiovascular disease?. Prog. Lipid Res. 2012, 51:314-324.